Comparable sales increased
The issuer reported 4.1% enterprise comparable-sales growth and raised FY27 guidance.
- Materiality
- Selected for the decision brief
- Board relevance
- Operating and market performance
- Evidence health
- 1 linked, 1 primary · reviewed 2026-08-30


